Biogen Idec Clears The Air: No Large Companies Meet Dual Test For Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
Putting a “permanent for sale sign out on the front lawn” is not the appropriate way to run the biotech either, CEO Mullen maintains.
You may also be interested in...
Amylin Speculation Intensifies, Part 2: Activist Shareholders Grow Restless
Eastbourne Capital says it wants Amylin to find a buyer. Is Lilly ready for another billion dollar deal?
Amylin Speculation Intensifies, Part 2: Activist Shareholders Grow Restless
Eastbourne Capital says it wants Amylin to find a buyer. Is Lilly ready for another billion dollar deal?
Icahn Leaves Pool, Genzyme Shareholder No More
Cambridge neighbor Biogen Idec, meanwhile, girds for a power struggle at its May annual meeting.